Y. Gu
Publications by Year
Research Areas
Psoriasis: Treatment and Pathogenesis, Hidradenitis Suppurativa and Treatments, Colorectal and Anal Carcinomas, Dermatology and Skin Diseases, Microscopic Colitis
Most-Cited Works
- → Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment(2014)206 cited
- → HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study(2015)191 cited
- → Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study(2016)97 cited
- → Association of hidradenitis suppurativa disease severity with increased risk for systemic comorbidities(2014)78 cited
- → Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension study(2012)59 cited
- → Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials(2019)55 cited
- → Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study(2012)48 cited
- Adalimumab for the treatment of moderate to severe hidradenitis suppurativa:A parallel randomized trial(2012)
- → Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis(2010)41 cited
- → Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study(2013)27 cited